Microlin Bio buys Marina Biotech's nucleic acid therapeutics assets in cash-and-stock deal

Microlin Bio buys Marina Biotech's nucleic acid therapeutics assets in cash-and-stock deal

Microlin Bio and Marina Biotech execute a term sheet under which Microlin intends to acquire Marina's nucleic acid therapeutics assets for 6.7M shares of Microlin stock and ~$1M in cash. Based on the recent price of $1.50 per share of MICB, the deal is valued at slightly more than $11M.

from Biotech News